ClinicalTrials.Veeva

Menu

Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery

E

Emad Abdel Aal Saliem

Status

Completed

Conditions

Pharmacological Action

Treatments

Drug: intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis

Study type

Interventional

Funder types

Other

Identifiers

NCT05428683
1221975

Details and patient eligibility

About

This study aims to evaluate the short-term effects and safety of prophylactic intra-vitreal injection of triamcinolone-moxifloxacin combination after cataract surgery. 84 patients underwent cataract surgery associated with intra-vitreal injection of triamcinolone-moxifloxacin combination after surgery.

Full description

All the patients underwent the surgical removal of cataract by the same surgeon according to the standard protocols for modern phacoemulsification. Surgery was done under local anesthesia by peri-bulbar injection of local anesthetic. All operations were performed in an operating room by using an operating microscope under complete aseptic condition by using 10% povidone iodine solution applied to the skin of eye lid, eye lashes, side of the nose, eye brow and the skin of forehead. Before the operation, sterile drape and eyelid speculum were used, then 5% povidone iodine solution was applied to the bulbar conjunctiva and fornices for about 5 minutes, then was irrigated by balanced salt solution (BSS).

All the patients were followed up at the 1st day, 1st week, 1st month and at the 3rd month after the operation. At each visit the followings should be assessed: the post-operative refraction, the best corrected visual acuity and anterior and posterior segments examination for any sign of postoperative inflammation as cells and flare. Intra-ocular pressure (IOP) assessment and optical coherence tomography (OCT) images were also taken at the 1st and the 3rd postoperative months to assess the central macular thickness in suspected cases of cystoid macular edema (CME) based upon symptoms or signs observed on fundus examination, were confirmed by OCT of the macula through subjective interpretation via presence of cysts or an objective measurement of retinal thickness > 250 microns.

Enrollment

84 patients

Sex

All

Ages

48 to 66 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria: Patients underwent uncomplicated cataract surgery with:

  • A significant cataract.
  • Good control of diabetes mellitus (DM) and hypertension (HPT) if present.
  • Visual acuity not less than hand movement (HM).

Exclusion criteria:

The followings were the exclusion criteria:

  • The use of systemic or topical steroids, topical ophthalmic antibiotics, or non-steroidal anti-inflammatory drugs (NSAIDs) for one week before operation.
  • Make an additional procedure at the same time with cataract surgery.
  • Those with uncontrolled glaucoma or with marked visual field defect .
  • Those with a significant macular edema due to DM, HPT, retinal vein occlusion (CRVO) or due to any previous inflammatory condition.
  • Those with blepharitis or any other local disease interfering with surgical intervention or affecting on the surgical outcome.
  • Occurrence of intraoperative complications as posterior capsular rupture or postoperative complications as retained lens fragment.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

84 participants in 1 patient group

prophylactic measures against post-operative inflammations
Other group
Description:
Usage of triamcinolone and moxifloxacin combination to be injected intravitreally by using 30 G needle.
Treatment:
Drug: intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems